(ALGS) Aligos Therapeutics, Inc. Business Model Canvas Research

Aligos Therapeutics, Inc.’s Merck NASH oligonucleotide collaboration is a research-and-development pact aimed at NASH-focused oligos, extending its liver-disease platform into metabolic disease. It also gives Aligos external validation from Merck, a major pharma partner, in a market where MASLD/MASH affects about 30% of adults worldwide.

• R&D deal, not a commercial launch
• Moves platform into metabolic disease
• Major pharma validation signal

Aligos Therapeutics, Inc. depends on clinical sites and investigators to run its Phase Ib and Phase I studies, because site execution drives patient enrollment, dosing, and data capture. Those relationships are central to advancing ALG-010133, ALG-000184, and ALG-055009 through early clinical readouts.

• Sites run first-in-human trials
• Investigators enroll patients
• They generate key efficacy data
• They de-risk the three lead programs

Aligos Therapeutics, Inc. treats strategic alliance management as a recurring core task: it runs licensing and collaboration deals with universities, biotech firms, and pharma partners to secure external IP and co-development rights. In its latest 2025 filings, the Company stayed a clinical-stage business, so these partnerships remain central to pipeline access and risk sharing.

• Manages licensing and collaboration contracts
• Buys access to external intellectual property
• Enables co-development with partners
• Supports recurring alliance execution

Aligos Therapeutics, Inc. runs the core clinical-stage work that keeps an IND active, quality systems aligned, and trials moving across multiple modalities. That means tight CMC control, vendor oversight, and site-level trial management so dose escalation can continue without gaps.

For a small biopharma, this is the gatekeeper job: one delay in manufacturing, release testing, or protocol execution can stall the next cohort. The focus is not just starting studies, but keeping supply and regulatory filings in lockstep through each program step.

• Support IND readiness and amendments
• Oversee CMC for multiple modalities
• Manage trial execution and cohort dosing

ALG-055009 is a small-molecule THR-ß agonist in Phase 1a/1b for NASH. It gives Aligos Therapeutics a non-viral liver disease program and helps diversify the pipeline beyond viral assets.

• Phase 1a/1b NASH asset
• Non-viral liver disease exposure
• Supports pipeline diversification

Aligos Therapeutics, Inc. uses partnership IP from Luxna, Emory, KU Leuven, and Merck, giving it four external technology sources instead of relying on one internal platform. Early Phase I and Phase Ib clinical data adds a second asset layer, so the company can reuse what it learned across multiple programs and keep more optionality.

• 4 licensed technology partners
• Phase I and Phase Ib data support de-risking
• Broader IP base improves platform leverage

Aligos Therapeutics, Inc. spans 2 liver-disease lanes: viral liver disease and metabolic liver disease. Its portfolio includes CHB and NASH-focused assets, so value is not tied to a single program; that wider mix lowers concentration risk and gives the company more shots at data-driven value creation.

• 2 disease areas: viral and metabolic
• CHB plus NASH assets reduce reliance on one readout

Aligos Therapeutics, Inc. uses partner-validated science through collaborations with Merck, Emory, Luxna, and KU Leuven, giving its programs external review from 4 named institutions. That kind of validation can strengthen credibility with regulators and investors, while also helping de-risk discovery and early development.

• 4 external collaborators
• Higher credibility
• Lower R&D risk

Aligos Therapeutics, Inc. keeps investor trust through regular SEC filings, trial updates, and clear readouts on its clinical programs. As a clinical-stage biotech with no approved products, each milestone and data release can move financing terms and partnering talks fast, so disclosure quality matters.

• Ongoing filings shape market view
• Trial readouts drive valuation
• Transparency supports fundraising

Aligos Therapeutics must work closely with health authorities such as the FDA and EMA during development; this feedback shapes protocol design, safety monitoring, and dose selection. This relationship matters before commercialization, because regulatory alignment can reduce trial risk and support later approval planning.

• Shaped by FDA and EMA feedback
• Guides protocol and dose choices
• Supports safety review before launch

Aligos Therapeutics, Inc. uses its corporate website and investor materials as its main public disclosure channel, posting SEC filings, pipeline updates, and milestone news for investors, analysts, and possible partners. For a public biotech, this matters because one disclosure stream can reach the full market at once, and the company has 1 primary website-based investor hub for those updates.

• Shares pipeline and milestone news

• Reaches investors and analysts

• Supports partner outreach

Aligos Therapeutics, Inc. uses IND filings, protocols, and study reports as its main channel to regulators and trial operators. These documents set trial rules, track development gates, and keep clinical work aligned with FDA oversight and site execution.

• INDs open the regulatory path.
• Protocols define trial conduct.
• Study reports prove progress.

Pharma and biotech partners like Merck and Luxna are business customers for licensing and co-development, and they pay for differentiated platforms that improve target access. This segment can also bring non-dilutive funding, which helps Aligos Therapeutics, Inc. extend runway without issuing new shares.

• Licensing drives upfront cash
• Co-development shares R&D risk
• Platform edge supports partner demand
• Non-dilutive funds reduce dilution

Academic researchers and clinical investigators help Aligos Therapeutics, Inc. move from target discovery to study execution. In 2025, this network mattered because translational work and trial operations depend on university labs, investigator sites, and expert feedback to keep R and D moving.

• Supports target discovery
• Runs translational studies
• Strengthens trial execution

Aligos Therapeutics, Inc.’s general and administrative expense covers public-company needs like legal, finance, HR, board work, and SEC reporting, so it supports the business outside the lab. In FY2025, this overhead stayed a key cash use alongside R&D, and it tends to rise when filing, governance, or staffing needs increase.

• Legal, finance, HR, board costs
• SEC filing and governance burden
• Non-lab corporate support expense

In FY2025, Aligos Therapeutics, Inc. can face upfront fees, milestone payments, and shared development costs under alliances; external IP lowers build time but raises cash outflows. For a biotech with limited scale, partnership economics can move R&D spend fast, so this line is a core cost driver.

• Upfront fees add near-term cash use
• Milestones create lumpy obligations
• Cost sharing can cut, but not erase, burn

As of FY2025, Aligos Therapeutics, Inc. reported no product revenue, so any royalty income would be back-ended and only start after a licensed asset wins regulatory approval and reaches launch. In biotech licensing, royalties are a common upside stream for partners, but for Aligos Therapeutics, Inc. they remain contingent on future commercialization.

• FY2025: no product sales
• Royalty income starts after launch
• Depends on licensed assets

Aligos Therapeutics, Inc. has no product sales yet; any revenue from this stream starts only if a pipeline asset wins approval and reaches market. The first likely launch areas are CHB, which affects about 254 million people worldwide, and NASH/MASH, where no approved Aligos product can generate sales today.

• Future, not current revenue
• Direct sales after approval
• Initial focus: CHB and NASH